Profitability
Weight: 25%
D
34
- 5yr Avg ROIC -2.5%
- Operating Margin Trend +82.03 pp/yr
KNSA
Kiniksa Pharmaceuticals International, plc
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 2 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
18
- 5yr Avg ROE 1.9%
- 5yr Share-Count CAGR 3.6%
Growth Quality
Weight: 25%
C+
61
- 5yr Revenue CAGR 104.8%
- 5yr EPS CAGR -33.9%
- Revenue-Growth Years (5) 4/5
Cash Generation
Weight: 20%
F
20
- 5yr FCF Margin -72.7%
- 5yr FCF/NI Conversion 0.47x
Balance Sheet
Weight: 10%
A+
100
- Net Debt / EBITDA -4.47x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 15.98
Stability
Weight: 5%
C-
45
- EPS Volatility (σ/μ) 1.06
- Piotroski F-Score 6
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 3 gurus held; 1 added; 2 trimmed.
- Holders
- 3
- Avg Δ position
- -9.5%
- New buys
- 0
- Full exits
- 0
- Cooperman decreased -23%
- Wood decreased -20%
- Greenblatt increased +14%